ES2052664T3 - Solucion de tratamiento de "ojo seco". - Google Patents

Solucion de tratamiento de "ojo seco".

Info

Publication number
ES2052664T3
ES2052664T3 ES88115984T ES88115984T ES2052664T3 ES 2052664 T3 ES2052664 T3 ES 2052664T3 ES 88115984 T ES88115984 T ES 88115984T ES 88115984 T ES88115984 T ES 88115984T ES 2052664 T3 ES2052664 T3 ES 2052664T3
Authority
ES
Spain
Prior art keywords
dry eye
treatment solution
phospholipid
eye
treatment composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88115984T
Other languages
English (en)
Inventor
Thomas Glonek
Jack V Greiner
Donald R Korb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocular Research of Boston Inc
Original Assignee
Ocular Research of Boston Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocular Research of Boston Inc filed Critical Ocular Research of Boston Inc
Application granted granted Critical
Publication of ES2052664T3 publication Critical patent/ES2052664T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

UN METODO Y COMPOSICION PARA EL TRATAMIENTO DEL "OJO SECO". EL METODO COMPRENDE LA APLICACION DE UN COMPLEJO FOSFOLIPIDO, CARGADO POSITIVA O NEGATIVAMENTE, A LA SUPERFICIE OCULAR. ES DESEABLE APLICAR EL FOSFOLIPIDO EN UN COMPUESTO DE TRATAMIENTO, PREFERIBLEMENTE EN FORMA DE EMULSION ACUOSA. EL COMPONENTE FOSFOLIPIDO DE LA COMPOSICION DEL TRATAMIENTO RESPONDE EN PIELES RASGADAS.
ES88115984T 1987-10-23 1988-09-28 Solucion de tratamiento de "ojo seco". Expired - Lifetime ES2052664T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/111,874 US4914088A (en) 1987-04-02 1987-10-23 Dry eye treatment solution and method

Publications (1)

Publication Number Publication Date
ES2052664T3 true ES2052664T3 (es) 1994-07-16

Family

ID=22340899

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88115984T Expired - Lifetime ES2052664T3 (es) 1987-10-23 1988-09-28 Solucion de tratamiento de "ojo seco".

Country Status (6)

Country Link
US (1) US4914088A (es)
EP (1) EP0312814B1 (es)
JP (1) JP3036749B2 (es)
AT (1) ATE80290T1 (es)
DE (1) DE3874479T2 (es)
ES (1) ES2052664T3 (es)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5278151A (en) * 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US5364632A (en) * 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
WO1991012808A1 (en) * 1990-02-22 1991-09-05 Macnaught Pty Limited Artificial tears
ZA912797B (en) * 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
EP0459148B1 (en) * 1990-05-29 1996-01-03 Ocular Research Of Boston Inc. Dry eye treatment composition
FR2673513B1 (fr) * 1991-03-05 1993-10-29 Institut Recherche Biologique Sa Nouvelles compositions dietetiques a base de lipides phosphoryles et leur utilisation dans l'amelioration des troubles de la vision.
ZA927277B (en) * 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US5290572A (en) * 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5830508A (en) * 1992-08-06 1998-11-03 Deo Corporation Composition for treating dry eye
EP0656779B1 (en) * 1992-08-28 2000-04-12 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles
TW274516B (es) * 1993-11-12 1996-04-21 Ciba Geigy Ag
DE69629230D1 (de) * 1995-03-24 2003-09-04 Ocular Res Of Bonton Inc Hydrogellinse mit Lipid-Vorbeschichtigung
DE19511322C2 (de) 1995-03-28 1999-09-02 Mann Gerhard Chem Pharm Fab Sterile Augengele mit einem Gehalt an mittelkettigen Triglyceriden und Verfahren zu deren Herstellung
US5616342A (en) * 1995-04-11 1997-04-01 Pdt, Inc. Emulsioin suitable for administering a poorly water-soluble photosensitizing compound and use thereof
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US5738856A (en) * 1995-11-03 1998-04-14 Ocular Research Of Boston, Inc. Skin care preparation and method
IL120005A (en) * 1997-01-14 2000-08-31 Ramot University Authority Of Pharmaceutical compositions for the treatment of the eye
ZA989513B (en) 1997-10-21 1999-04-21 Alcon Lab Inc Compositions containing histamine H2 agonists and methods of use in treating dry eye
EP0982025A1 (en) * 1998-08-28 2000-03-01 Wilhelm Prof. Dr. Stoffel Synthetic tear fluid
WO2000038690A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of dry eye
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
EP1156809B1 (en) 1999-03-01 2005-12-07 Vista Scientific LLC Mucin containing ophthalmic preparations
US6429194B1 (en) * 1999-03-01 2002-08-06 Vista Scientific Llc Mucin containing ophthalmic preparation
CN1387505A (zh) 1999-11-09 2002-12-25 爱尔康公司 含羟基二十碳四烯酸衍生物的组合物和用于治疗干眼病的方法
ES2215740T3 (es) 1999-11-09 2004-10-16 Alcon Inc. Homologos de 15-hete con sustitucion 3-heteroatomica y dos carbonos, y metodo de uso.
WO2001034129A2 (en) 1999-11-09 2001-05-17 Alcon Universal Ltd. Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use
US6803385B2 (en) 1999-11-09 2004-10-12 Alcon, Inc. Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
AU8031400A (en) 1999-11-09 2001-06-06 Alcon Universal Limited 15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
WO2001034553A2 (en) 1999-11-09 2001-05-17 Alcon Universal Ltd. 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
AU1226001A (en) 1999-11-09 2001-06-06 Alcon Universal Limited Phospholipids of hydroxyeicosatetraenoic acid-like derivatives
AU775290B2 (en) 1999-11-09 2004-07-29 Alcon Inc. Omega chain modified 15-hydroxyeicosatetraenoic acid derivatives and methods of their use for the treatment of dry eye
BR0015404A (pt) 1999-11-09 2002-06-25 Alcon Inc Compostos relacionados com ácido 15-hidroxieicosatetraenóico e métodos de uso
WO2001034144A1 (en) 1999-11-09 2001-05-17 Alcon Universal Ltd. Lipoxin a4 and its analogs for the treatment of dry eye
WO2001034552A2 (en) 1999-11-09 2001-05-17 Alcon Universal Ltd. Benzenoid derivatives of 15-hydroxyeicosatetraenoic acid and methods of their use in treating dry eye disorders
US6458854B2 (en) 1999-11-09 2002-10-01 Alcon Universal Ltd. Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
US6552084B2 (en) 1999-11-09 2003-04-22 Alcon Universal Ltd. Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
DK1228028T3 (da) 1999-11-09 2005-11-14 Alcon Inc Hydroxyicosatetraenoatsalte, præparater og fremgangsmåder til anvendelse til behandling af öjentörhedslidelser
AU2603301A (en) 1999-12-22 2001-07-03 Alcon Universal Limited 6-keto prostaglandin F1alpha and analogs for treating dry eye
US7112588B2 (en) * 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
JP2004531560A (ja) * 2001-05-21 2004-10-14 アルコン，インコーポレイテッド ドライアイ障害を処置する方法
DK1392355T3 (da) 2001-05-21 2007-04-30 Alcon Inc Anvendelse af proteasominhibitorer tilbehandling af öjentörhedslidelser
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
PL367286A1 (en) 2001-05-21 2005-02-21 Alcon, Inc. Use of nfkb inhibitors to treat dry eye disorders
US6645994B1 (en) 2001-06-01 2003-11-11 Alcon, Inc. Method of treating dry eye disorders
US6750250B1 (en) * 2001-07-12 2004-06-15 Alcon, Inc. 11,12-oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders
DE10141018A1 (de) * 2001-08-22 2003-03-13 Eth Zuerich Eidgenoessische Te Verwendung von negativ geladenen Phospholipiden, sowie Zusammensetzungen umfassend Phospholipide zur Behandlung des Auges
US20040214754A1 (en) * 2001-10-03 2004-10-28 Ellis Edward J. Ophthalmic preparation containing glycomacropeptide
US20040220089A1 (en) * 2001-10-03 2004-11-04 Ellis Edward J. Ophthalmic preparation containing glycoprotein
US20030109488A1 (en) * 2001-10-11 2003-06-12 Alcon, Inc. Methods for treating dry eye
US20030109508A1 (en) * 2001-10-11 2003-06-12 Alcon, Inc. Methods for treating dry eye
US20030109509A1 (en) * 2001-10-11 2003-06-12 Alcon, Inc. Methods for treating dry eye
US6656460B2 (en) 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
CA2484512C (en) * 2002-05-17 2013-04-16 Othera Pharmaceuticals, Inc. Treatment of cataracts and other ophthalmic diseases
US7897642B1 (en) * 2002-06-19 2011-03-01 Dr. Irvine Dubow Compositions and methods for dry eye syndrome
US8420699B1 (en) 2002-06-19 2013-04-16 Irvine L. Dubow Composition and methods of treatment using deionized and ozonated solution
EP1542768A1 (en) * 2002-09-20 2005-06-22 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
DE60323520D1 (de) * 2002-10-18 2008-10-23 Joel S Echols Dreischichtige tränenformulierung
US7051156B2 (en) 2002-11-06 2006-05-23 Synology Inc. Raid-5 disk having cache memory
WO2004060274A2 (en) * 2002-12-20 2004-07-22 Alcon, Inc. Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells
WO2004093878A1 (en) * 2003-04-16 2004-11-04 Alcon, Inc. Use of fused pyridazine derivatives for treating dry eye disorders
US7825134B2 (en) * 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases
US20050182039A1 (en) * 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye
US20050202097A1 (en) * 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
US8455016B2 (en) 2004-03-12 2013-06-04 Melbj Holdings, Llc Treatment for meibomian gland dysfunction or obstruction
DE602005016392D1 (de) 2004-03-25 2009-10-15 Bausch & Lomb Verwendung von loteprednoletabonat zur behanldung von trockenen augen
JP4993299B2 (ja) * 2004-05-14 2012-08-08 アルコン，インコーポレイテッド ドライアイ障害およびブドウ膜炎を処置するための方法
US7923471B2 (en) * 2004-05-14 2011-04-12 Alcon, Inc. Method of treating dry eye disorders and uveitis
JP2008505177A (ja) * 2004-07-01 2008-02-21 ザ・シェペンズ・アイ・リサーチ・インスティテュート・インコーポレーテッド 目の障害および状態を治療するための組成物および方法
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
US7223737B1 (en) 2004-08-13 2007-05-29 Alcon, Inc. Method of treating dry eye disorders using glycosides
WO2006065916A1 (en) * 2004-12-14 2006-06-22 Alcon, Inc. Method of treating dry eye disorders using 13(s)-hode and its analogs
US9161905B2 (en) 2005-01-12 2015-10-20 Ocular Research Of Boston, Inc. Dry eye treatment
DK2564843T3 (en) 2005-06-01 2019-03-11 Bioelectron Tech Corp Redox-active therapeutics for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers
US8950405B2 (en) * 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US20080114423A1 (en) * 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US7981095B2 (en) * 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US7981146B2 (en) * 2006-05-15 2011-07-19 Tearscience Inc. Inner eyelid treatment for treating meibomian gland dysfunction
US20070016256A1 (en) * 2005-07-18 2007-01-18 Korb Donald R Method and apparatus for treating gland dysfunction
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US20090043365A1 (en) * 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US20070110812A1 (en) * 2005-11-14 2007-05-17 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
ES2284398B2 (es) 2006-04-27 2008-12-16 Universidad Complutense De Madrid Formulacion de vesiculas liposomales en soluciones acuosas con caracteristicas de pelicula lagrimal.
US8128674B2 (en) * 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8007524B2 (en) * 2006-05-15 2011-08-30 Tearscience, Inc. Heat treatment and heat loss reduction for treating meibomian gland dysfunction
US9314369B2 (en) * 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US8137390B2 (en) * 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US7981147B2 (en) * 2006-05-15 2011-07-19 Tearscience, Inc. Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7976573B2 (en) * 2006-05-15 2011-07-12 Tearscience, Inc. Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8128673B2 (en) * 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
EP2051736A2 (en) * 2006-07-07 2009-04-29 Bausch & Lomb Incorporated Compositions comprising a dissociated glucocorticoid receptor agonist and an immunosuppressive agent for treating dry eye
WO2008027069A1 (en) * 2006-08-21 2008-03-06 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid
US20080057022A1 (en) * 2006-08-30 2008-03-06 Erning Xia Ophthalmic Pharmaceutical Compositions and Uses Thereof
WO2008052037A2 (en) * 2006-10-24 2008-05-02 Alcon Research, Ltd. Packaging materials for formulations containing 2-pyrrolidone derivatives
US20080095863A1 (en) * 2006-10-24 2008-04-24 Alcon Manufacturing Ltd. 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US20080188573A1 (en) * 2007-02-02 2008-08-07 Alcon Research, Ltd. Use of thy1-fp transgenic mouse for the identification of ophthalmic agents
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
USD613408S1 (en) 2008-02-06 2010-04-06 Tearscience, Inc. Eye treatment head gear
USD617443S1 (en) 2008-02-06 2010-06-08 Tearscience, Inc. Eye treatment goggles
US8314153B2 (en) 2008-09-10 2012-11-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US8539938B2 (en) * 2009-03-12 2013-09-24 Ford Global Technologies, Llc Fuel systems and methods for controlling fuel systems in a vehicle with multiple fuel tanks
EA031126B1 (ru) 2009-04-28 2018-11-30 Биоэлектрон Текнолоджи Корпорейшн Способ лечения доминантной атрофии зрительного нерва токотриенол-хинонами
USD638128S1 (en) 2009-10-06 2011-05-17 Tearscience, Inc. Ocular device design
TWI478730B (zh) 2009-12-03 2015-04-01 Alcon Res Ltd 眼科乳劑
US8658614B2 (en) 2010-08-13 2014-02-25 The University of Texas Health Science Center Aptamer-containing compositions and methods for targeting E-selectin
US9161531B2 (en) 2011-02-23 2015-10-20 Donald R. Korb High alcohol content sanitizer
RU2460517C1 (ru) * 2011-07-14 2012-09-10 Федеральное государственное учреждение "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Фармацевтическая композиция для комплексного лечения заболеваний глазной поверхности у больных с первичной открытоугольной глаукомой
US8859525B2 (en) 2011-07-19 2014-10-14 Bausch & Lomb Incorporated Pharmaceutical compositions comprising mushroom-based polysaccharides and uses thereof
RU2470630C1 (ru) * 2011-07-28 2012-12-27 Общество с ограниченной ответственностью "Научно-производственная компания "ФАРМАСОФТ" (ООО "НПК "ФАРМАСОФТ") Средство для лечения воспалительных заболеваний глаз человека и животных, для стимуляции репаративных процессов и эпителизации
EP2758031A1 (en) 2011-09-22 2014-07-30 Bausch & Lomb Incorporated Ophthalmic gel compositions
WO2014031857A2 (en) 2012-08-22 2014-02-27 Tearscience, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
ES2942724T3 (es) 2013-04-30 2023-06-06 Alcon Inc Sistemas para el tratamiento de enfermedades del ojo
WO2015138604A1 (en) 2014-03-12 2015-09-17 University Of Virginia Patent Foundation Compositions and methods for treating eye infections and disease
WO2015171516A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
CN107074884A (zh) 2014-06-18 2017-08-18 西蒂斯制药有限责任公司 活性剂的矿物质氨基酸复合物
WO2017079734A1 (en) 2015-11-05 2017-05-11 University Of Louisville Research Foundation, Inc. Local and regional anesthesia and analgesia
CN108712903A (zh) 2015-12-17 2018-10-26 生物电子技术有限公司 用于治疗氧化应急障碍的氟烷基、氟代烷氧基、苯氧基、杂芳氧基、烷氧基和胺1,4-苯醌衍生物
CA3026264A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth
TW201938141A (zh) 2018-02-21 2019-10-01 瑞士商諾華公司 基於脂質的眼用乳劑
US11147737B2 (en) 2018-02-26 2021-10-19 Olympic Ophthalmics, Inc. Handheld device with motorized member for treatment of disorders
US11253395B2 (en) 2018-06-01 2022-02-22 Aurora Tears Technology, Inc. Systems and methods for generating and applying biomimicry tear films
CN112566542A (zh) * 2018-06-01 2021-03-26 奥罗拉的眼泪科技有限公司 一种用于产生和施加仿生泪膜的系统和方法
US11278493B2 (en) 2018-12-10 2022-03-22 EternaTear, Inc. Ophthalmic formulations providing durable ocular lubrication
EP4104818A1 (en) 2021-06-17 2022-12-21 Skeye Pharma GbR Ophthalmic composition comprising xanthohumol
EP4104817A1 (en) 2021-06-17 2022-12-21 Skeye Pharma GbR Ophthalmic composition comprising astragaloside iv
US11679078B1 (en) 2022-03-08 2023-06-20 EternaTear, Inc. Ophthalmic formulations and related methods
US11471475B1 (en) 2022-03-08 2022-10-18 Ralph P. Stone Ophthalmic suspension vehicles and related methods for pharmaceutical ingredient delivery
WO2023187672A1 (en) 2022-03-31 2023-10-05 Alcon Inc. Ophthalmic compositions
EP4302767A1 (en) 2022-07-04 2024-01-10 Skeye Pharma GmbH Ophthalmic composition comprising eriocitrin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869482A (en) * 1972-07-31 1975-03-04 Etapharm Chem Pharm Lab G M B Method of producing highly purified phosphatides
US4677099A (en) * 1981-09-04 1987-06-30 Yeda Research And Development Co., Ltd. Medical processes employing a novel lipid fraction
AU564876B2 (en) * 1982-03-29 1987-08-27 Liposome Company, Inc., The Stable plurilamellar vesicles
JPS59500952A (ja) * 1982-03-29 1984-05-31 ザ　リポソ−ム　カンパニ−、インコ−ポレ−テッド 安定なプルリラメラベシクル類
US4421748A (en) * 1982-07-13 1983-12-20 Trager Seymour F Artificial tear aid
FR2596651B1 (fr) * 1986-04-08 1989-11-10 Centre Nat Rech Scient Nouveaux liposomes a base de phosphatidylinositolmannosides, et compositions pharmaceutiques les contenant
EP0316345A1 (en) * 1986-07-28 1989-05-24 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue

Also Published As

Publication number Publication date
EP0312814B1 (en) 1992-09-09
US4914088A (en) 1990-04-03
ATE80290T1 (de) 1992-09-15
DE3874479D1 (de) 1992-10-15
JP3036749B2 (ja) 2000-04-24
JPH01146824A (ja) 1989-06-08
DE3874479T2 (de) 1993-02-18
EP0312814A1 (en) 1989-04-26

Similar Documents

Publication Publication Date Title
ES2052664T3 (es) Solucion de tratamiento de "ojo seco".
ATE132366T1 (de) Zusammensetzung zur behandlung von dry eye erkrankungen
BR8707438A (pt) Processo e dispositivo de lente intraocular para tratamento faquico de miopia
BE844544A (fr) Insert ophtalmique pour le traitement du syndrome de l'oeil sec
DE69116186D1 (de) Medikament zum Halten ophthalmologischer Mittel im Augengewebe und Verfahren zu seiner Herstellung
DE3785602D1 (de) Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augen-hypertension und glaukom.
SE8305864D0 (sv) Ogondroppar
RU94015599A (ru) Применение n - ацетил-l - цистеина и его производных для регулирования образования морщин кожи и/или атрофии кожи, композиция на основе n - ацетил - l - цистеина и его производных
ATE102825T1 (de) Behandlung von mastitis und appliziereinrichtung dafuer.
DE3865368D1 (de) Thiophensulfonamide zur behandlung von glaukom.
ATE42680T1 (de) Verfahren und ''kit'' zur desinfektion von kontaktlinsen.
FI911131A0 (fi) Menetelmä viherkaihia estävien 3-aryylikarbonyyli-1-aminoalkyyli-1H-indoliyhdisteiden valmistamiseksi
DE68904462D1 (de) 4-chinolincarbonsaeure-derivate, brauchbar zur behandlung von haut- und muco-epithelial-gewebekrankheiten.
ES2032529T3 (es) Una emulsion de agua y aceite termo-esterilizable.
ATE148628T1 (de) 5-methylisoxazol-4-carbonsäure-anilide und 2- hydroxyethyliden-cyanoessigsäure-anilide zur behandlung von augenkrankheiten
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
NO173657C (no) Antiblokkemiddel, anveldelse derav, samt fremgangsmaate ved antiblokkingsbehandling
FI882387A0 (fi) Menetelmä taudinaiheuttajien inaktivoimiseksi biologisessa tai farmaseuttisessa aineessa
DE58902451D1 (de) (s)-emopamil zur anwendung bei der behandlung von migraene.
BE873515A (fr) Procede et dispositif pour le traitement d'articles de fumeurs
ZA814523B (en) Salt of furosemide or piretanide as the acid component and penbutolol or (-).3-(4)-(3-(3,4-dimethoxyphenylethylamino)-2-hydroxy-proposy)-phenyl)crotononitrile as the base component,process for its prepration,composition in which it is present and its use
FR2595243B3 (fr) Couteau pour la chirurgie du segment anterieur de l'oeil
SE8000157L (sv) Forfarande och sammansettning for behandling av kontaktlinser
DE69021548D1 (de) Verfahren und Vorrichtung zur Nassbehandlung von Textilmaterialien sowie zur Wiedereinstellung eines Behandlungsbades.
DE3174977D1 (en) Bioactive composition containing vegetable agents

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 312814

Country of ref document: ES